All In Biotech

Drug Trial Radar · NCT06461429

PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]

Platform for Adaptive Trials in Perinatal Units (Core Protocol)

Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 100,000 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

100,000

Planned (sponsor's estimate)

Start

Nov 1, 2025

Primary completion

Dec 31, 2050

Study completion Dec 31, 2050

Sponsor

Lead sponsor
University of MelbourneAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Auckland, New Zealand; Monash University; The University of Western Australia; La Trobe University; The University of New South Wales; University of Tasmania; Menzies School of Health Research; University of Adelaide; University of Sydney; Mater Medical Research Institute
First posted
Jun 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PLATIPUS is an adaptive platform trial aimed at improving the health of infants born preterm (before 37 weeks' gestation). PLATIPUS will compare how different treatments and care provided to pregnant women and people at risk of preterm birth and infants born preterm affect infant health. The main questions PLATIPUS aims to answer are: 1. What effect/s do different treatments/care provided to pregnant women and people at risk of preterm birth have on the health of their infants? (Pregnancy domains) 2. What effect/s do different treatments/care given to infants born preterm have on their health ? (Neonatal domains). This registration record relates to the PLATIPUS Core (or 'master') protocol which provides guidance for the overall running of the trial. Additional appendices will outline the aims, questions, treatments, and activities for each separate research question (domain). Each Domain-Specific Appendix will be registered separately on ClinicalTrials.gov and will link to this record.

Conditions

  • Preterm Birth

Interventions

  • ErythromycinDrug

    Antibiotic. Standard of care. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).

  • Amoxicillin and ErythromycinDrug

    Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).

  • AzithromycinDrug

    Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).

  • Caffeine citrate 20 mg/kg load and 10 mg/kg daily maintenance.Drug

    Lower dose caffeine: 20mg/kg load and 10mg/kg/day maintenance. Standard of care. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.

  • Caffeine citrate 30 mg/kg load and 15 mg/kg daily maintenance.Drug

    Medium dose caffeine: 30mg/kg load and 15 mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.

  • Caffeine citrate 40 mg/kg load and 20 mg/kg daily maintenanceDrug

    Higher dose caffeine: 40mg/kg load and 20mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who progress by at least one level higher on the PLATIPUS Ordinal Outcome ScaleTime frame: At any time prior to 42 weeks' postmenstrual age or first discharge home from hospital (whichever is earlier).

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.